IRhythm Technologies Inc. $(IRTC)$ has announced the results from two significant real-world studies at the American Diabetes Association's 85th Scientific Sessions (ADA 2025) in San Francisco. The studies focused on cardiac arrhythmias in patients with type 2 diabetes, some of whom also have chronic kidney disease. The findings indicate that cardiac arrhythmias are common and often occur early in these patients, frequently preceding major cardiovascular events. The analyses utilized longitudinal claims data from over 30 million U.S. adults, highlighting the potential for enhanced early detection strategies in at-risk populations. These results underscore the importance of monitoring patients based on unique risk factors rather than symptoms alone, as many arrhythmias are asymptomatic.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。